98%
921
2 minutes
20
Introduction: Primary debulking surgery (PDS), interval debulking surgery (IDS), and platinum-based chemotherapy are the current standard treatments for advanced ovarian cancer (OC). The time to initiation of adjuvant chemotherapy (TTC) could influence patient outcomes.
Methods: We conducted a multicenter retrospective cohort study of advanced (International Federation of Gynecology and Obstetrics (FIGO) stage III or IV) OC treated between 2014 and 2018 to assess progression-free survival (PFS) and overall survival (OS) in relation to TTC. All patients underwent a germline multigene panel for BRCA1/2 evaluation.
Results: Among the 83 patients who underwent PDS, a TTC ≥ 60 days was associated with a shorter PFS (hazard ratio (HR) 2.02, 95% confidence interval (CI) 1.04-3.93, = 0.038), although this association lost statistical significance when adjusting for residual disease (HR 1.52, 95% CI 0.75-3.06, = 0.244, for TTC and HR 2.73, 95% CI 1.50-4.96, = 0.001, for residual disease). Among 52 IDS patients, we found no evidence of an association between TTC and clinical outcomes. Ascites, type of chemotherapy, or germline BRCA1/2 mutational status did not influence TTC and were not associated with clinical outcomes in PDS or IDS patients.
Discussion: In conclusion, longer TTC seems to negatively affect prognosis in patients undergoing PDS, especially those with residual disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468566 | PMC |
http://dx.doi.org/10.3389/fonc.2023.1221096 | DOI Listing |
Nat Genet
September 2025
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Aberrant DNA methylation has been described in nearly all human cancers, yet its interplay with genomic alterations during tumor evolution is poorly understood. To explore this, we performed reduced representation bisulfite sequencing on 217 tumor and matched normal regions from 59 patients with non-small cell lung cancer from the TRACERx study to deconvolve tumor methylation. We developed two metrics for integrative evolutionary analysis with DNA and RNA sequencing data.
View Article and Find Full Text PDFJ Pediatr Urol
August 2025
Hacettepe University Medical Faculty, Department of Pediatric Surgery, Ankara, Turkey.
Background: Patients with synchronous bilateral Wilms tumor (BWT) face challenges in balancing oncological control and nephron-sparing surgery (NSS). This study aimed to identify objective criteria for NSS in BWT by applying SIOP RTSG 2016 Umbrella Study criteria, the RENAL nephrometry scoring system, three-dimensional (3D) tumor volume measurements, and residual healthy kidney volume assessment.
Methods: A retrospective analysis was conducted on 14 patients with synchronous BWT.
Clin Lymphoma Myeloma Leuk
August 2025
The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, KS; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; U.S Myeloma Innovations Research Collaborative, Kansas City, KS. Electronic addres
Background: Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a key treatment for acute myeloid leukemia (AML). Measurable residual disease (MRD) predicts post-transplant outcomes. This study evaluates the impact of pretransplant MRD status on outcomes in AML patients undergoing allo-HCT.
View Article and Find Full Text PDFJACC Cardiovasc Interv
September 2025
Division of Vascular Surgery, Department of Surgery, the Jikei University School of Medicine, Tokyo, Japan.
Background: Long-term comparative data on drug-eluting stents (DES) and drug-coated balloons (DCB) for femoropopliteal artery (FPA) disease remain limited.
Objectives: The authors sought to compare 3-year outcomes of DES vs DCB without bailout stenting in FPA disease.
Methods: We retrospectively analyzed 1,406 patients from a multicenter registry who underwent endovascular therapy for FPA using DES (n = 342) or DCB (n = 1,064) after the successful lesion preparation.
Comput Methods Programs Biomed
August 2025
The Institute of Cancer Research, London, UK. Electronic address:
Background And Objective: Apparent Diffusion Coefficient (ADC) values and Total Diffusion Volume (TDV) from Whole-body diffusion-weighted MRI (WB-DWI) are recognised cancer imaging biomarkers. However, manual disease delineation for ADC and TDV measurements is unfeasible in clinical practice, demanding automation. As a first step, we propose an algorithm to generate fast and reproducible probability maps of the skeleton, adjacent internal organs (liver, spleen, urinary bladder, and kidneys), and spinal canal.
View Article and Find Full Text PDF